INDIANAPOLIS (AP) -- Amylin Pharmaceuticals says a federal court issued an injunction preventing drug development partner Eli Lilly from using the same sales force to sell an Amylin-developed diabetes treatment and a competitor's.
Amylin says the temporary restraining order prevents Lilly from continuing with a plan to sell both Byetta and Boehringer Ingelheim's linagliptin. Amylin and Lilly entered an agreement in 2002 to develop and sell Byetta, a type 2 diabetes treatment.
Lilly also entered a development agreement with Germany's Boehringer Ingelheim in January. Earlier this month, regulators approved linagliptin, which also treats type 2 diabetes. Amylin then filed a lawsuit against Lilly over that arrangement.
Lilly says it is disappointed in the court's decision but will take the necessary steps to comply with the order.
Amylin says the temporary restraining order prevents Lilly from continuing with a plan to sell both Byetta and Boehringer Ingelheim's linagliptin. Amylin and Lilly entered an agreement in 2002 to develop and sell Byetta, a type 2 diabetes treatment.
Lilly also entered a development agreement with Germany's Boehringer Ingelheim in January. Earlier this month, regulators approved linagliptin, which also treats type 2 diabetes. Amylin then filed a lawsuit against Lilly over that arrangement.
Lilly says it is disappointed in the court's decision but will take the necessary steps to comply with the order.